Key stats
About ProShares Ultra Nasdaq Biotechnology
Home page
Inception date
Apr 7, 2010
Structure
Open-Ended Fund
Replication method
Synthetic
Dividend treatment
Distributes
Distribution tax treatment
Ordinary income
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
ProShare Advisors LLC
Distributor
SEI Investments Distribution Co.
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQs biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returnsfor good or for ill.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Government
Stocks77.26%
Health Technology68.96%
Finance1.02%
Commercial Services0.86%
Technology Services0.60%
Health Services0.42%
Process Industries0.02%
Bonds, Cash & Other22.74%
Government30.23%
Miscellaneous0.00%
Cash−7.49%
Stock breakdown by region
North America88.78%
Europe10.88%
Asia0.31%
Oceania0.03%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history